Literature DB >> 22806892

Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia.

Junko Baba1, Satoshi Watanabe, Yu Saida, Tomohiro Tanaka, Takao Miyabayashi, Jun Koshio, Kosuke Ichikawa, Koichiro Nozaki, Toshiyuki Koya, Katsuya Deguchi, Chunrui Tan, Satoru Miura, Hiroshi Tanaka, Junta Tanaka, Hiroshi Kagamu, Hirohisa Yoshizawa, Ko Nakata, Ichiei Narita.   

Abstract

Cytotoxic lymphodepletion therapies augment antitumor immune responses. The generation and therapeutic efficacy of antitumor effector T cells (T(E)s) are enhanced during recovery from lymphopenia. Although the effects of lymphodepletion on naive T cells (T(N)s) and T(E)s have been studied extensively, the influence of lymphodepletion on suppressor cells remains poorly understood. In this study, we demonstrate a significant increase of CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) in sublethally irradiated lymphopenic mice. These radio-resistant Tregs inhibited the induction of T(E)s in tumor-draining lymph-nodes (TDLNs) during recovery from lymphopenia. The transfer of T(N)s into lymphopenic tumor-bearing mice resulted in some antitumor effects; however, Treg depletion after whole-body irradiation and reconstitution strongly inhibited tumor progression. Further analyses revealed that tumor-specific T cells were primed from the transferred T(N)s, whereas the Tregs originated from irradiated recipient cells. As in irradiated lymphopenic mice, a high percentage of Tregs was observed in cyclophosphamide-treated lymphopenic mice. The inhibition of Tregs in cyclophosphamide-treated mice significantly reduced tumor growth. These results indicate that the Tregs that survive cytotoxic therapies suppress antitumor immunity during recovery from lymphopenia and suggest that approaches to deplete radio and chemo-resistant Tregs can enhance cancer immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22806892     DOI: 10.1182/blood-2012-02-411124

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  The interplay between cancer associated fibroblasts and immune cells in the context of radiation therapy.

Authors:  Miles Piper; Adam C Mueller; Sana D Karam
Journal:  Mol Carcinog       Date:  2020-05-04       Impact factor: 4.784

Review 2.  Clinical utility of natural killer cells in cancer therapy and transplantation.

Authors:  David A Knorr; Veronika Bachanova; Michael R Verneris; Jeffrey S Miller
Journal:  Semin Immunol       Date:  2014-03-05       Impact factor: 11.130

3.  Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3⁺ regulatory T cells.

Authors:  Wim Pierson; Bénédicte Cauwe; Antonia Policheni; Susan M Schlenner; Dean Franckaert; Julien Berges; Stephanie Humblet-Baron; Susann Schönefeldt; Marco J Herold; David Hildeman; Andreas Strasser; Philippe Bouillet; Li-Fan Lu; Patrick Matthys; Antonio A Freitas; Rita J Luther; Casey T Weaver; James Dooley; Daniel H D Gray; Adrian Liston
Journal:  Nat Immunol       Date:  2013-07-14       Impact factor: 25.606

4.  PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer.

Authors:  Miho Takahashi; Satoshi Watanabe; Ryo Suzuki; Masashi Arita; Ko Sato; Miyuki Sato; Yuki Sekiya; Yuko Abe; Toshiya Fujisaki; Aya Ohtsubo; Satoshi Shoji; Koichiro Nozaki; Kosuke Ichikawa; Rie Kondo; Yu Saida; Satoshi Hokari; Nobumasa Aoki; Masachika Hayashi; Yasuyoshi Ohshima; Toshiyuki Koya; Toshiaki Kikuchi
Journal:  Cancer Immunol Immunother       Date:  2021-10-17       Impact factor: 6.968

5.  Selective Treg reconstitution during lymphopenia normalizes DC costimulation and prevents graft-versus-host disease.

Authors:  Holly A Bolton; Erhua Zhu; Alexandra M Terry; Thomas V Guy; Woon-Puay Koh; Sioh-Yang Tan; Carl A Power; Patrick Bertolino; Katharina Lahl; Tim Sparwasser; Elena Shklovskaya; Barbara Fazekas de St Groth
Journal:  J Clin Invest       Date:  2015-08-24       Impact factor: 14.808

6.  Blockade of TNF-α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion.

Authors:  Li-Yuan Chang; Yung-Chang Lin; Jy-Ming Chiang; Jayashri Mahalingam; Shih-Huan Su; Ching-Tai Huang; Wei-Ting Chen; Chien-Hao Huang; Wen-Juei Jeng; Yi-Cheng Chen; Shi-Ming Lin; I-Shyan Sheen; Chun-Yen Lin
Journal:  Oncoimmunology       Date:  2015-04-16       Impact factor: 8.110

7.  TGF-β1 mediates the radiation response of prostate cancer.

Authors:  Chun-Te Wu; Ching-Chuan Hsieh; Tzu-Chen Yen; Wen-Cheng Chen; Miao-Fen Chen
Journal:  J Mol Med (Berl)       Date:  2014-09-18       Impact factor: 4.599

Review 8.  Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.

Authors:  Guillaume Grisay; Julien Pierrard; Caterina Confente; Emmanuel Seront
Journal:  Curr Treat Options Oncol       Date:  2020-12-02

Review 9.  Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

Authors:  Irena Adkins; Jitka Fucikova; Abhishek D Garg; Patrizia Agostinis; Radek Špíšek
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

10.  Cyclophosphamide-Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management.

Authors:  Sumandeep Dhesi; Michael P Chu; Gregg Blevins; Ian Paterson; Loree Larratt; Gavin Y Oudit; Daniel H Kim
Journal:  J Investig Med High Impact Case Rep       Date:  2013-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.